 The main endpoint will be to determine whether the Lipiocis treatment reduces the percentage of recurrence from 50 to 20 at 24 months. The secondary end-points will be the overall survival, the survival without recurrence of the primary tumor, the survival without new tumor, the deterioration of hepatocellular function and the side effects of the Lipiocis treatment. 